

Add the following:**Cetirizine Hydrochloride Tablets****DEFINITION**

Cetirizine Hydrochloride Tablets contain NLT 90.0% and NMT 110.0% of $C_{21}H_{25}ClN_2O_3 \cdot 2HCl$.

IDENTIFICATION

- The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the *Assay*.

ASSAY**PROCEDURE**

Solution A: 2 N sulfuric acid and water (2:33)

Buffer: 2.9 mL/L of phosphoric acid in water

Mobile phase: Acetonitrile and *Buffer* (3:7)

Diluent: Acetonitrile, *Solution A*, and water (100:1:100)

Standard solution: 0.2 mg/mL of USP Cetirizine Hydrochloride RS in *Diluent*

Sample solution: 0.2 mg/mL of cetirizine hydrochloride in *Diluent*, from NLT 20 powdered Tablets. [NOTE—Sonicate, if necessary.]

Chromatographic system

(See *Chromatography* <621>, *System Suitability*.)

Mode: LC

Detector: UV 230 nm

Column: 4.6-mm × 25-cm; 5-μm packing L1

Flow rate: 1.5 mL/min

Injection size: 10 μL

Run time: 1.3 times the retention time of cetirizine

System suitability

Sample: *Standard solution*

Suitability requirements

Tailing factor: NMT 2.0

Relative standard deviation: NMT 2.0%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of $C_{21}H_{25}ClN_2O_3 \cdot 2HCl$ in the portion of Tablets taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

- r_U = peak response from the *Sample solution*
- r_S = peak response from the *Standard solution*
- C_S = concentration of USP Cetirizine Hydrochloride RS in the *Standard solution* (mg/mL)
- C_U = nominal concentration of cetirizine hydrochloride in the *Sample solution* (mg/mL)

Acceptance criteria: 90.0%–110.0%

PERFORMANCE TESTS**DISSOLUTION** <711>

Medium: Water; 900 mL, degassed

Apparatus 2: 50 rpm

Time: 30 min

Buffer: 2.9 mL/L of phosphoric acid in water

Mobile phase: Acetonitrile and *Buffer* (2:3)

Standard solution: 11 μg/mL of USP Cetirizine Hydrochloride RS in water. This solution can be stored for 48 h at room temperature.

Sample solution: Pass a portion of the solution under test through a suitable 0.45-μm filter.

Chromatographic system

(See *Chromatography* <621>, *System Suitability*.)

Mode: LC

Detector: UV 230 nm

Column: 4.6-mm × 25-cm; 5-μm packing L1

Flow rate: 1 mL/min

Injection size: 50 μL

Run time: 1.3 times the retention time of cetirizine

System suitability

Sample: *Standard solution*

Suitability requirements

Tailing factor: NMT 2.0

Relative standard deviation: NMT 2.0%

Calculate the percentage of cetirizine dissolved:

$$\text{Result} = (r_U/r_S) \times (C_S/L) \times V \times 100$$

r_U = peak response from the *Standard solution*

r_S = peak response from the *Sample solution*

C_S = concentration of the *Standard solution* (mg/mL)

L = Tablet label claim, mg

V = volume of *Medium*, 900 mL

Tolerances: NLT 80% (Q) of the labeled amount of cetirizine hydrochloride is dissolved.

- UNIFORMITY OF DOSAGE UNITS** (905): Meet the requirements

IMPURITIES**Organic Impurities****PROCEDURE**

Solution A: 2 N sulfuric acid and water (2:33)

Buffer: 3.4 g/L of tetrabutyl ammonium hydrogen sulfate in water

Diluent: Acetonitrile, *Solution A*, and water (910:27:63)

Mobile phase: Acetonitrile, *Solution A*, and *Buffer* (93:5:2)

Standard solution: 1.5 μg/mL of USP Cetirizine Hydrochloride RS in *Diluent*

Sample solution: 0.5 mg/mL of cetirizine hydrochloride in *Diluent*, from NLT 20 powdered Tablets. [NOTE—Sonicate, if necessary.]

Chromatographic system

(See *Chromatography* <621>, *System Suitability*.)

Mode: LC

Detector: UV 230 nm

Column: 4.0-mm × 25-cm; 5-μm packing L3

Flow rate: 0.8 mL/min

Injection size: 20 μL

Run time: 2.5 times the retention time of cetirizine

System suitability

Sample: *Standard solution*

Suitability requirements

Tailing factor: NMT 2.0

Relative standard deviation: NMT 10.0%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of each impurity in the portion of Tablets taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (1/F) \times 100$$

r_U = peak response of each impurity from the *Sample solution*

r_S = peak response for cetirizine from the *Standard solution*

C_S = concentration of USP Cetirizine Hydrochloride RS in the *Standard solution* (mg/mL)

C_U = nominal concentration of cetirizine hydrochloride in the *Sample solution* (mg/mL)

F = relative response factor (see *Impurity Table 1*)

Acceptance criteriaIndividual impurities: See *Impurity Table 1*.

Total impurities: NMT 0.8%

Impurity Table 1

Name	Relative Retention Time	Relative Response Factor	Acceptance Criteria, NMT (%)
Cetirizine lactose ester ^a	0.56	1.0	0.40
Cetirizine	1.0	—	—
Cetirizine ethanol ^b	1.67	1.2	0.15
Any unspecified degradation product	—	—	0.2


^a 6-O-[2-(2-{4-[(4-Chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetyl]-β-D-galactopyranosyl-(1→4)β-D-glucopyranose.^b 2-[4-[(4-Chlorophenyl)(phenyl)methyl]piperazin-1-yl]ethanol.**ADDITIONAL REQUIREMENTS**

- **PACKAGING AND STORAGE:** Preserve in well-closed containers, and store below 30°.

- **USP REFERENCE STANDARDS (11)**
USP Cetirizine Hydrochloride RS_{11S} (USP35)

Anhydrous Citric Acid

Portions of the monograph text that are national *USP* text, and are not part of the harmonized text, are marked with symbols (✦) to specify this fact.



C₆H₈O₇ 192.1
1,2,3-Propanetricarboxylic acid, 2-hydroxy-;
Citric acid [77-92-9].

DEFINITION

Anhydrous Citric Acid contains NLT 99.5% and NMT 100.5% of C₆H₈O₇, calculated on the anhydrous basis.

IDENTIFICATION

- **A. INFRARED ABSORPTION (197K):** Dry the substance to be examined at 105° for 2 h.

ASSAY• **PROCEDURE**

Sample: 0.550 g of Anhydrous Citric Acid; record weight accurately.

Analysis: Dissolve the *Sample* in 50 mL of water. Add 0.5 mL of phenolphthalein TS. Titrate with 1 N sodium hydroxide VS. Each mL of 1 N sodium hydroxide is equivalent to 64.03 mg of C₆H₈O₇.

Acceptance criteria: 99.5%–100.5% on the anhydrous basis

IMPURITIES

- **RESIDUE ON IGNITION (281):** NMT 0.1%, determined on 1.0 g

- **HEAVY METALS (231):** NMT 10 µg/g✦

• **SULFATE**

Standard sulfate solution A: 1.81 mg/mL of potassium sulfate in 30% alcohol. Immediately before use, transfer 10.0 mL of this solution to a 1000-mL volumetric flask, dilute with 30% alcohol to volume, and mix. This solution contains 10 µg/mL of sulfate.

Standard sulfate solution B: 1.81 mg/mL of potassium sulfate in water. Immediately before use, transfer 10.0

mL of this solution to a 1000-mL volumetric flask, dilute with water to volume, and mix. This solution contains 10 µg/mL of sulfate.

Sample stock solution: 66.7 mg/mL of Anhydrous Citric Acid

Sample solution: To 4.5 mL of *Standard sulfate solution A*, add 3 mL of a barium chloride solution (1 in 4), shake, and allow to stand for 1 min. To 2.5 mL of the resulting suspension, add 15 mL of the *Sample stock solution* and 0.5 mL of 5 N acetic acid, and mix.

Standard solution: Prepare as directed for the *Sample solution*, except use 15 mL of *Standard sulfate solution B* instead of the *Sample stock solution*.

Analysis

Samples: *Sample solution* and *Standard solution*

Acceptance criteria: Any turbidity produced in the *Sample solution* after 5 min standing is not greater than that produced in the *Standard solution* (0.015%).

- **LIMIT OF ALUMINUM** (where it is labeled as intended for use in dialysis)

Standard aluminum solution: To 352 mg of aluminum potassium sulfate in a 100-mL volumetric flask, add a few mL of water, swirl to dissolve, add 10 mL of diluted sulfuric acid, dilute with water to volume, and mix. Immediately before use, dilute 1.0 mL of this solution with water to 100.0 mL.

pH 6.0 acetate buffer: Dissolve 50 g of ammonium acetate in 150 mL of water, adjust with glacial acetic acid to a pH of 6.0, dilute with water to 250 mL, and mix.

Sample solution: Dissolve 20.0 g of Anhydrous Citric Acid in 100 mL of water, and add 10 mL of pH 6.0 acetate buffer. Extract this solution with successive portions of 20, 20, and 10 mL of a 0.5% solution of 8-hydroxyquinoline in chloroform, combining the chloroform extracts in a 50-mL volumetric flask. Dilute the combined extracts with chloroform to volume, and mix.

Standard solution: Prepare a mixture of 2.0 mL of *Standard aluminum solution*, 10 mL of pH 6.0 acetate buffer, and 98 mL of water. Extract this mixture as described for the *Sample solution*, dilute the combined extracts with chloroform to volume, and mix.

Blank solution: Prepare a mixture of 10 mL of pH 6.0 acetate buffer and 100 mL of water. Extract this mixture as described for *Sample solution*, dilute the combined extracts with chloroform to volume, and mix.

Fluorometric conditions

Excitation wavelength: 392 nm

Emission wavelength: 518 nm

Analysis

Samples: *Sample solution* and *Standard solution*

Determine the fluorescence intensities of the *Samples* in a fluorometer set as directed under *Fluorometric conditions*, using the *Blank solution* to set the instrument to zero.

Acceptance criteria: The fluorescence of the *Sample solution* does not exceed that of the *Standard solution* (0.2 ppm).

Change to read:• **LIMIT OF OXALIC ACID**

Sample stock solution: 0.80 g of Anhydrous Citric Acid in 4 mL of water_{1S} (USP35)

Sample solution: To_{1S} (USP35) the *Sample stock solution* add 3 mL of hydrochloric acid and 1 g of granular zinc, boil for 1 min, and allow to stand for 2 min. Transfer the supernatant to a test tube containing 0.25 mL of a phenylhydrazine hydrochloride solution (1 in 100), and heat to boiling. Cool rapidly, transfer to a graduated cylinder, and add an equal volume of hydrochloric acid and 0.25 mL of a potassium ferricyanide solution (1 in 20). Shake, and allow to stand for 30 min.

Standard solution: Prepare as directed for the *Sample solution*, except use 4 mL of 0.10 mg/mL oxalic acid